ライフサイエンスコーパス: hallucinogen

1 rotonin transporter, and is unlikely to be a hallucinogen.

2 e one of the most potent naturally occurring hallucinogens.

3 phenethylamines derived from the 2C class of hallucinogens.

4 anisms responsible for the unique effects of hallucinogens.

5 signaling pattern and behavioral response to hallucinogens.

6 ion of the more flexible phenethylamine type hallucinogens.

7 amate is a common mechanism in the action of hallucinogens.

8 become more widely used in the U.S. as legal hallucinogens.

9 get responsible for the actions of classical hallucinogens.

10 n, synthesize, extract, identify, and ingest hallucinogens.

11 c illness and the psychotomimetic effects of hallucinogens.

12 ast new light on the mechanisms of action of hallucinogens.

13 sedatives, stimulants, cocaine, opiates, and hallucinogens.

14 , which can be mimicked by administration of hallucinogens.

15 sed stereotypical behavioral response to the hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI), an a

16 gs used in this context include serotonergic hallucinogens, amphetamine, and NMDA receptor antagonist

17 o controls consistent with its activity as a hallucinogen and a tremorogen.

18 ing-methylated derivatives of the well-known hallucinogen and entactogen MDA (1a) were synthesized an

19 ecstasy is currently classified as a type of hallucinogen and its withdrawal is not recognized in the

20 ions for the inactivity of 6-fluoro-DET as a hallucinogen and to determine the effects of fluorinatio

21 Both hallucinogens and 3,4-methylenedioxymethamphetamine (MDM

22 d essential role in mediating the actions of hallucinogens and atypical antipsychotic drugs at 5-HT(2

23 serotonin receptors respond to the action of hallucinogens and atypical antipsychotic drugs, we have

24 the principal molecular targets for LSD-like hallucinogens and atypical antipsychotic drugs.

25 t a low addictive potential similar to other hallucinogens and consistent with kappa opiate receptor

26 irus, with increased head-twitch response to hallucinogens and diminished antipsychotic-like effect o

27 ing in the mPFC to the behavioral actions of hallucinogens and further support the targeting of mGlu2

28 The behavioral responses to hallucinogens and glutamate antipsychotics are both affe

29 receptor (GPCR) that mediates the effects of hallucinogens and is the target of a number of commonly

30 cts were identified for structurally similar hallucinogens and nonhallucinogens and found to correspo

31 togen because of its affinities to classical hallucinogens and stimulants.

32 Why only certain 2AR agonists are hallucinogens and which neural circuits mediate their ef

33 ith such pharmacologically distinct ligands, hallucinogens, and nonhallucinogens obtained from all-at

34 The 5-HT(2A) receptor is a target of several hallucinogens, antipsychotics, anxiolytics, and antidepr

35 he signaling and behavioral responses to the hallucinogens are distinct.

36 characterize the extent of information about hallucinogens available to Internet users.

37 DMT acts as a hallucinogen, but its receptor target has been unclear.

38 utic potential, and in drugs of abuse (e.g., hallucinogens, central stimulants, empathogens), the lat

39 ed PFC population activity, the serotonergic hallucinogen DOI dose-dependently decreased population a

40 Unexpectedly, the phenethylamine hallucinogen, DOI, a partial agonist at 5-HT(2A/2C) rece

41 esults have led to the widely held idea that hallucinogens elicit their effect by modulating synaptic

42 es, including persistent migraine aura, post-hallucinogen flashback, or psychogenic disorder.

43 discriminate serotonin-releasing agents and hallucinogens from saline.

44 norin A, the most potent naturally occurring hallucinogen, has attracted an increasing amount of atte

45 n amphetamine, cannabis, club drug, cocaine, hallucinogen, heroin, nonheroin opioid, sedative/tranqui

46 rchers conducted extensive investigations of hallucinogens in the 1950s and 1960s.

47 otentially promising clinical application of hallucinogens in the treatment of anxiety reactive to ad

48 nd may contribute to the specific effects of hallucinogens in this class.

49 T cells in the DRN induced by phenethylamine hallucinogens in vivo.

50 Hallucinogens, including mescaline, psilocybin, and lyse

51 0.6 mg/kg, i.p.), which is a phenethylamine hallucinogen, increased glutamate to 206% above saline-t

52 hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness.

53 hallucinations of the blind), schizophrenia, hallucinogen-induced states and epilepsy.

54 The illicit use of hallucinogens is reemerging in the United States, especi

55 Hallucinogen-like activity was evaluated in the two-leve

56 Hallucinogen-like activity, evaluated in the two-lever d

57 valuated using in vivo behavioral assays for hallucinogen-like and 5-HT(1A) agonist activity and in v

58 DOI from saline were employed to assess the hallucinogen-like behavioral properties of these rigid t

59 receptors, making it one of the most potent hallucinogen-like phenylalkylamine derivatives reported

60 The prototypical hallucinogen LSD acts via serotonin receptors, and here

61 The hallucinogen lysergic acid diethylamide (LSD; 0.1 mg/kg,

62 report biochemical studies showing that the hallucinogen lysergic acid diethylamide, its precursor e

63 inctive profile compared with the prototypic hallucinogen lysergic acid diethylamide.

64 Hallucinogens mediate many of their psychoactive effects

65 aromatic methoxy groups in the prototypical hallucinogen, mescaline (1).

66 f 11 days, and the group was subdivided into hallucinogen-preferring users (n = 10) and MDMA-preferri

67 , -32%); no significant changes were seen in hallucinogen-preferring users.

68 d the effects of acute administration of the hallucinogen psilocybin (.16 mg/kg) versus placebo on am

69 Although the serotonergic hallucinogen psilocybin activates multiple serotonin (5-

70 et search techniques, the authors located 81 hallucinogen-related sites and categorized the informati

71 e and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates was as

72 We will discuss marijuana, cocaine, opioids, hallucinogens, solvents and the newer so-called rave or

73 ic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural respons

74 The hallucinogens studied [d-lysergic acid diethylamide, psi

75 ists may lack the intoxicating properties of hallucinogens such as LSD.

76 Classic hallucinogens such as lysergic acid diethylamide are tho

77 The effects of hallucinogens, such as psilocybin and mescaline, require

78 posed mechanism of action for phenethylamine hallucinogens, that such compounds must be full agonists

79 The ability of hallucinogens to increase extracellular glutamate in the

80 gs and reduce the ability of psychotomimetic hallucinogens to increase glutamatergic transmission.

81 We found evidence that MDMA but not hallucinogen use is associated with changes in the cereb

82 For any drug use and for cannabis and hallucinogen use, model fitting suggested that twin rese

83 ncy sites offering cautionary material about hallucinogen use.

84 Using the Internet, potential hallucinogen users can bypass traditional channels of me

85 ) and consumption of illicit drugs (five, no hallucinogens) were rare.